Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

NeoPharm's CRADA agreement for IL-13 receptor research extended

March 1, 2001

Positive quality-of-life and survival results reported for Maxim's Ceplene

March 1, 2001

FDA requests further information for Campath BLA

Feb. 23, 2001

Vical broadens clinical development of Allovectin-7

Feb. 22, 2001

Therion Biologics and the NCI move CEA-TRICOM cancer vaccine to phase I

Feb. 22, 2001

Phase II trials of SMART 1D10 antibody begin in non-Hodgkin's lymphoma

Feb. 21, 2001

Virulizin granted orphan drug status by FDA

Feb. 20, 2001

Distribution agreement for Pacis BCG terminated by UroCor and BioChem Pharma

Feb. 20, 2001

Melacine now available in Canada for treatment of stage IV melanoma

Feb. 16, 2001

Patient enrollment complete in phase IIb trial of IL-2 gene medicine for H&N cancer

Feb. 16, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 21, 2026.
Biohaven reports details on discovery of BHV-2100
BioWorld Science
Transient receptor potential melastatin 3 (TRPM3) is a calcium-permeable TRP channel that is highly expressed in somatosensory neurons, including nociceptors of...
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
New GABA(B) receptor PAMs revealed in Addex Pharma patents
BioWorld Science
Addex Pharma SA has disclosed new GABA(B) receptor positive allosteric modulators (PAMs) potentially useful for the treatment of chronic cough, urinary...
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...